Agios Pharmaceuticals Inc (NASDAQ:AGIO) CEO David P. Schenkein sold 49,374 shares of the company’s stock in a transaction on Wednesday, May 23rd. The shares were sold at an average price of $90.40, for a total value of $4,463,409.60. Following the completion of the transaction, the chief executive officer now owns 49,374 shares of the company’s stock, valued at $4,463,409.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Agios Pharmaceuticals stock traded down $0.04 during mid-day trading on Friday, hitting $97.47. The stock had a trading volume of 9,166 shares, compared to its average volume of 355,508. The stock has a market cap of $5.73 billion, a price-to-earnings ratio of -14.50 and a beta of 2.00. Agios Pharmaceuticals Inc has a 12 month low of $50.91 and a 12 month high of $99.82.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.03). The firm had revenue of $8.80 million during the quarter, compared to the consensus estimate of $11.93 million. Agios Pharmaceuticals had a negative net margin of 822.32% and a negative return on equity of 61.70%. Agios Pharmaceuticals’s revenue was down 16.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.56) EPS. research analysts predict that Agios Pharmaceuticals Inc will post -6.24 earnings per share for the current fiscal year.
A number of research analysts recently commented on the company. BidaskClub lowered Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday. Piper Jaffray Companies reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 4th. Credit Suisse Group set a $95.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 7th. ValuEngine upgraded Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Finally, Citigroup initiated coverage on Agios Pharmaceuticals in a research note on Wednesday, May 23rd. They set a “buy” rating and a $117.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Agios Pharmaceuticals currently has an average rating of “Buy” and an average price target of $95.55.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.